IL309385A - Methods for treating the decrease in bone mineral density with Krengel inhibitors containing transmembrane protein 1 (KREMEN1) - Google Patents
Methods for treating the decrease in bone mineral density with Krengel inhibitors containing transmembrane protein 1 (KREMEN1)Info
- Publication number
- IL309385A IL309385A IL309385A IL30938523A IL309385A IL 309385 A IL309385 A IL 309385A IL 309385 A IL309385 A IL 309385A IL 30938523 A IL30938523 A IL 30938523A IL 309385 A IL309385 A IL 309385A
- Authority
- IL
- Israel
- Prior art keywords
- kremen1
- inhibitors
- methods
- transmembrane protein
- bone mineral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163218212P | 2021-07-02 | 2021-07-02 | |
| PCT/US2022/035783 WO2023278741A1 (en) | 2021-07-02 | 2022-06-30 | Methods of treating decreased bone mineral density with kringle containing transmembrane protein 1 (kremen1) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309385A true IL309385A (en) | 2024-02-01 |
Family
ID=82748403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309385A IL309385A (en) | 2021-07-02 | 2022-06-30 | Methods for treating the decrease in bone mineral density with Krengel inhibitors containing transmembrane protein 1 (KREMEN1) |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230021584A1 (https=) |
| EP (1) | EP4363585A1 (https=) |
| JP (1) | JP2024524375A (https=) |
| KR (1) | KR20240043752A (https=) |
| CN (1) | CN117836412A (https=) |
| AU (1) | AU2022300984A1 (https=) |
| CA (1) | CA3222830A1 (https=) |
| IL (1) | IL309385A (https=) |
| WO (1) | WO2023278741A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118298911B (zh) * | 2024-04-12 | 2024-11-22 | 中山大学孙逸仙纪念医院 | 一种多部位慢性疼痛潜在治疗靶点确定系统 |
-
2022
- 2022-06-30 CN CN202280057215.XA patent/CN117836412A/zh active Pending
- 2022-06-30 WO PCT/US2022/035783 patent/WO2023278741A1/en not_active Ceased
- 2022-06-30 JP JP2023580472A patent/JP2024524375A/ja active Pending
- 2022-06-30 US US17/855,053 patent/US20230021584A1/en active Pending
- 2022-06-30 IL IL309385A patent/IL309385A/en unknown
- 2022-06-30 KR KR1020247003956A patent/KR20240043752A/ko active Pending
- 2022-06-30 AU AU2022300984A patent/AU2022300984A1/en active Pending
- 2022-06-30 EP EP22748568.7A patent/EP4363585A1/en active Pending
- 2022-06-30 CA CA3222830A patent/CA3222830A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240043752A (ko) | 2024-04-03 |
| JP2024524375A (ja) | 2024-07-05 |
| US20230021584A1 (en) | 2023-01-26 |
| EP4363585A1 (en) | 2024-05-08 |
| AU2022300984A1 (en) | 2024-01-04 |
| CN117836412A (zh) | 2024-04-05 |
| WO2023278741A1 (en) | 2023-01-05 |
| CA3222830A1 (en) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025001648A (es) | Inhibidores del oncogen homologo del virus de sarcoma de rata kirsten (kras) | |
| IL288395A (en) | Mat2a tricyclic inhibitors and methods for use in cancer therapy | |
| MX2025015502A (es) | Inhibidores del oncogén de sarcoma de rata de kirsten (kras) | |
| ZA202206163B (en) | Methods of treating coronavirus | |
| IL309385A (en) | Methods for treating the decrease in bone mineral density with Krengel inhibitors containing transmembrane protein 1 (KREMEN1) | |
| IL319131A (en) | Methods for treating solid tumors with activating alterations in the FGFR3 gene | |
| MX2020007431A (es) | Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto oseo. | |
| IL310590A (en) | Methods of treating migraine with MNK inhibitors | |
| ZA202210984B (en) | Methods of treating coronavirus disease 2019 | |
| IL312466A (en) | PI3K-alpha inhibitors and methods for their preparation and use | |
| EP3989883C0 (en) | PLUG-SHAPED IMPLANT FOR REPLACING AND REGENERATING BIOLOGICAL TISSUE AND METHOD FOR PRODUCING THE IMPLANT | |
| HK40110983A (en) | Methods of treating decreased bone mineral density with kringle containing transmembrane protein 1 (kremen1) inhibitors | |
| IL314581A (en) | Treatment methods using P-TAU181 LEVEL | |
| IL320711A (en) | Treatment methods | |
| EP4316119A4 (en) | METHOD AND APPARATUS FOR IMPROVED CANDIDATE ASSIGNMENT SCHEMES FOR EXTENDED PDCCH | |
| IL300113A (en) | Compressed cyclic RAF inhibitors and methods of using them | |
| EP4176717A4 (en) | COCCIDIOSIS CONTROL AGENT AND METHOD OF USING COCCIDIOSIS CONTROL AGENT | |
| ZA202210033B (en) | Apparatus for improved transfection efficiency and/or protein expression and method of use thereof | |
| IL310276A (en) | Methods for treating reduced bone mineral density with differentiation group 109 inhibitors | |
| GB202201824D0 (en) | Methods of treatment | |
| GB202106202D0 (en) | An improved method of treating slurry and improved slurry inoculant | |
| IL326541A (en) | Methods for transferring audio data and associated devices | |
| IL289086A (en) | Methods and preparations for the treatment of hemophilia and low mineral bone density | |
| IL316872A (en) | Methods for selective treatment of tendinopathy using interleukin-17 (IL-17) antagonists | |
| ZA202212737B (en) | Tissue culture and rapid propagation method for thamnocharis esquirolii |